A single center phase 1b/2 trail to identified suitable dosage and its efficacy of modified
FLOT regime in Chinese gastric cancer patients. This trial is designed to identified
recommended phase II dose (RP2D) of modified FLOT in Chinese patients, and to evaluate the
efficacy of modified FLOT regime as first-line for advanced or metastatic gastric cancer.
This trial is in 2 stages: the first stage will establish the maximum tolerated dose (MTD)
and RP2D of docetaxel and oxaliplatin in FLOT regime. In the second stage, the efficacy of
modified FLOT will be assessed by response rate.